PROPOSER SON EXPERTISE
Low levels of cholesterol carried by high-density lipoprotein (HDL) has an indisputable value as a predictor of elevated cardiovascular (CV) risk. As a consequence, HDL-cholesterol (HDL-C) concentration is present in all existing calculators of CV risk.
However, elevation of HDL-C levels using therapeutic approaches do not necessarily reduce CV risk. Indeed, patients with high levels of HDL-C might also be at risk for CV disease.
It has been suggested that CV risk is not reflected by HDL quantity, but rather by HDL function. Existing methods to evaluate HDL function do not however allow explaining excessive risk at high HDL-C levels.
Team from Sorbonne Université has designed a new diagnostic tool to better assess cardiovascular disease risk associated with HDL.
The technology is based on the quantification of the HDL role in the lipolysis allowing to determine the key function of HDL reflecting CV risk.
• Better evaluation of cardiovascular risk as compared to traditional measurement of HDL-C
• Prediction of cardiovascular risk in metabolic diseases
• Stratification of patients with cardiovascular disease
A validation tested case-control study is being performed on 120 plasma samples from a 10-year follow-up of subjects who subsequently developed CV disease.
• The diagnostic is simple and fast
• The test requires only minimal volumes of plasma
• The test improves evaluation of CV risk as compared to traditional lipid screening
• The test can better assess the efficiency of a treatment for CV disease.